Drugs group Bioglan Pharma, which specialises in skin disease treatments and pain relief, today boosted its presence in Germany by snapping up a portfolio of dermatology products for £16.4 million.
The group is buying 12 prescription products for the treatment of various skin diseases, including steroid, anti-fungal, anti-viral and acne drugs, from German pharmaceuticals group Hexal.
Mr Terry Sadler, Bioglan's chairman and chief executive said: "It would be hard to find a better deal for Bioglan in Germany."
Mr Sadler, who bought Bioglan in 1985 and floated it in 1998, said the buy gave Bioglan a "ready-made dermatology portfolio" to add to its existing products.
Dermatology is already the biggest contributor to Bioglan's product sales - generating 62 per cent in the last financial year.
Bioglan also today said it had entered an agreement with Swedish group Stiftelsen Industrifonden to issue 500,000 shares to cancel an outstanding loan arrangement.
Stiftelsen had part-funded a drug delivery research and development programme at Biogram, a Swedish group which Bioglan bought in 1996.
PA